Lausanne, Switzerland (ots/PRNewswire) - Sommet Educationis the only hospitality education group with two Swiss higher education institutions, Glion and Les Roches, in the top four for Hospitality and Leisure Management education in the QS World University Rankings 2021. According to global higher education analysts ...
Lausanne, Switzerland and Seongnam-si Gyeonggi-do, Republic of Korea (ots) - Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading ...
Lausanne, Switzerland (ots/PRNewswire) - - Although essential for public health, new online survey findings show that people with self-reported rosacea* may be experiencing worsening of symptoms due to mask wearing, further increasing the daily burden for people living with this chronic skin disease - Despite ...
Lausanne, Switzerland (ots/PRNewswire) - Sommet Education, the Leading Education Group in Hospitality with Glion Institute of Higher Education, Les Roches and Ecole Ducasse, has created a one-of-a-kind virtual student Fair around hospitality, culinary and pastry arts, luxury, innovation, digital programs. Glion, Les Roches and École Ducasse offer an exceptional portfolio of graduate and post-graduate programs focusing on ...
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy ...
Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Kathy L. Hibbs was nominated to the company's Board of Directors and its Audit Committee. Hibbs is an accomplished healthcare technology executive, currently holding the position of Chief Legal ...
Tel Aviv, Israel / Lausanne, Switzerland (ots) - Nucleai (www.Nucleaimd.com), a global provider in pathology-based biomarker discovery, and Debiopharm (www.debiopharm.com), a Swiss-based biopharmaceutical company specializing in drug development, announced that they have entered into a long-term collaboration to ...
Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Bram Goorden joined its Executive team, holding the dual role of Chief Commercial Officer and Head of North America. Goorden comes to SOPHiA from Foundation Medicine Inc. (Cambridge, MA) where he held the role of VP of International Business and ...
Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...
Lausanne, Switzerland and Boston (ots/PRNewswire) - Supporting the Company's Global Expansion to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine - SOPHiA GENETICS enters next stage of its global expansion with oversubscribed Series F round exceeding $110 million, led by major health-tech fund and followed by strategic industry leader - Company ...
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Lausanne, Switzerland (ots) - Promising overall survival outcomes at 3-years for high-risk, locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) patients observed with Debio 1143 + CRT Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the release of ...
Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...
Lausanne, Switzerland (ots/PRNewswire) - Healthcare professionals (HCPs) encouraged to investigate true impacts beyond the visible, empower patients with knowledge and aim for 'clear' (IGA 0) skin to improve outcomes A new expert-authored Galderma report (https://hosted.bmj.com/rosaceabeyondthevisible) released ...
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be responsible for Marketing, Product Management and Business Development. Lara Hashimoto joined the healthcare industry 20 years ago holding ...
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, today announced that it is entering the fight against the COVID-19 coronavirus by extending its partnership with Paragon Genomics, who developed a next-generation sequencing (NGS) assay and leveraging the SOPHiA Platform analytical capabilities, as well as delivering ...
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors, effective March 1, 2020. He is replacing Antoine Duchateau, who has served as chairman since 2013 and will continue as a board member. Cox joined the ...
MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...
New 'Face up to rosacea' campaign comprising online content and a downloadable, personalized patient appointment guide, equips people living with the distressing skin disease to seek expert support to help break the cycle of rosacea and aim for long-term treatment success Lausanne, Switzerland (ots/PRNewswire) - ...
Lausanne, Switzerland, and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Gaëtan Fraikin and Sergei Yakneen have joined its executive team as Chief Marketing Officer and Chief Information Officer, respectively. Mr. Fraikin and Mr. Yakneen bring decades of highly ...
Experts also welcome upsurge in the adoption of a rosacea signs and symptoms ('phenotype') led approach in clinical practice and announce the launch of prototype clinical tools to support physicians to optimize rosacea management Lausanne, Switzerland (ots/PRNewswire) - Published online in the British Journal of ...
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...
Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland (ots/PRNewswire) - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development ...
A community of medical professionals sharing ideas and solving problems Lausanne, Switzerland (ots/PRNewswire) - LigneSante (https://lignesante.com/) today announced their online communication platform for healthcare professionals. The desire to connect to a collective knowledge around the management of diseases, aware that very often the complexity of medical ...
Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...
Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...
As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this ...
Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...